Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

collegium pharmaceutical inc - COLL

COLL

Close Chg Chg %
30.00 0.41 1.37%

Closed Market

30.41

+0.41 (1.37%)

Volume: 457.44K

Last Updated:

Nov 21, 2024, 4:00 PM EDT

Trade Now

Company Overview: collegium pharmaceutical inc - COLL

COLL Key Data

Open

$29.96

 Day Range

29.96 - 30.95

52 Week Range

25.16 - 42.29

 Market Cap

$967.51M

Shares Outstanding

32.25M

 Public Float

31.08M

Beta

0.95

 Rev. Per Employee

N/A

P/E Ratio

12.94

 EPS

$2.74

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

449.88K

  

COLL Performance

1 Week
 
 2.81%
 
1 Month
 
 -12.36%
 
3 Months
 
 -16.13%
 
1 Year
 
 16.78%
 
5 Years
 
 57.16%
 

COLL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About collegium pharmaceutical inc - COLL

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

COLL At a Glance

Collegium Pharmaceutical, Inc.
100 Technology Center Drive
Stoughton, Massachusetts 02072
Phone 1-781-713-3699 Revenue 566.77M
Industry Pharmaceuticals: Major Net Income 48.16M
Sector Health Technology 2023 Sales Growth 22.166%
Fiscal Year-end 12 / 2024 Employees 197
View SEC Filings

COLL Valuation

P/E Current 12.944
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 23.80
Price to Sales Ratio 2.269
Price to Book Ratio 5.019
Price to Cash Flow Ratio 4.682
Enterprise Value to EBITDA 5.081
Enterprise Value to Sales 2.911
Total Debt to Enterprise Value 0.409

COLL Efficiency

Revenue/Employee 2,876,989.848
Income Per Employee 244,441.624
Receivables Turnover 3.157
Total Asset Turnover 0.489

COLL Liquidity

Current Ratio 1.174
Quick Ratio 1.103
Cash Ratio 0.678

COLL Profitability

Gross Margin 57.549
Operating Margin 30.958
Pretax Margin 13.362
Net Margin 8.496
Return on Assets 4.156
Return on Equity 24.678
Return on Total Capital 5.537
Return on Invested Capital 6.755

COLL Capital Structure

Total Debt to Total Equity 345.024
Total Debt to Total Capital 77.529
Total Debt to Total Assets 58.976
Long-Term Debt to Equity 250.708
Long-Term Debt to Total Capital 56.336
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Collegium Pharmaceutical Inc - COLL

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
310.02M 276.87M 463.93M 566.77M
Sales Growth
+4.49% -10.69% +67.56% +22.17%
Cost of Goods Sold (COGS) incl D&A
130.18M 127.99M 252.34M 240.60M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
61.61M 68.94M 134.39M 149.26M
Depreciation
927.00K 1.75M 2.92M 3.50M
Amortization of Intangibles
60.68M 67.18M 131.47M 145.76M
COGS Growth
-32.78% -1.68% +97.16% -4.65%
Gross Income
179.84M 148.88M 211.59M 326.17M
Gross Income Growth
+74.53% -17.21% +42.12% +54.15%
Gross Profit Margin
+58.01% +53.77% +45.61% +57.55%
2020 2021 2022 2023 5-year trend
SG&A Expense
123.60M 123.74M 142.19M 150.71M
Research & Development
- 9.77M 7.71M 1.30M
Other SG&A
113.83M 116.03M 140.89M 150.71M
SGA Growth
-2.51% +0.11% +14.91% +5.99%
Other Operating Expense
- - - -
-
Unusual Expense
- 7.51M 36.08M 32.00M
EBIT after Unusual Expense
56.23M 17.63M 33.32M 143.46M
Non Operating Income/Expense
232.00K 12.00K 1.05M 15.62M
Non-Operating Interest Income
232.00K 12.00K 1.05M 15.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
28.88M 21.01M 63.21M 83.34M
Interest Expense Growth
+3,077.34% -27.24% +200.81% +31.84%
Gross Interest Expense
28.88M 21.01M 63.21M 83.34M
Interest Capitalized
- - - -
-
Pretax Income
27.58M (3.37M) (28.85M) 75.73M
Pretax Income Growth
+221.39% -112.23% -754.98% +362.53%
Pretax Margin
+8.90% -1.22% -6.22% +13.36%
Income Tax
830.00K (74.89M) (3.85M) 27.58M
Income Tax - Current - Domestic
- 3.14M 4.71M 29.73M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (78.03M) (8.55M) (2.15M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
26.75M 71.52M (25.00M) 48.16M
Minority Interest Expense
- - - -
-
Net Income
26.75M 71.52M (25.00M) 48.16M
Net Income Growth
+217.74% +167.33% -134.96% +292.60%
Net Margin Growth
+8.63% +25.83% -5.39% +8.50%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
26.75M 71.52M (25.00M) 48.16M
Preferred Dividends
- - - -
-
Net Income Available to Common
26.75M 71.52M (25.00M) 48.16M
EPS (Basic)
0.7775 2.047 -0.7391 1.4272
EPS (Basic) Growth
+214.47% +163.28% -136.11% +293.10%
Basic Shares Outstanding
34.41M 34.94M 33.83M 33.74M
EPS (Diluted)
0.761 1.8563 -0.7391 1.2933
EPS (Diluted) Growth
+212.04% +143.93% -139.82% +274.98%
Diluted Shares Outstanding
35.15M 41.05M 33.83M 41.79M
EBITDA
117.84M 94.08M 203.79M 324.72M
EBITDA Growth
+1,581.88% -20.17% +116.63% +59.34%
EBITDA Margin
+38.01% +33.98% +43.93% +57.29%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 42.25
Number of Ratings 5 Current Quarters Estimate 1.505
FY Report Date 12 / 2024 Current Year's Estimate 6.163
Last Quarter’s Earnings 1.61 Median PE on CY Estimate N/A
Year Ago Earnings 5.47 Next Fiscal Year Estimate 6.578
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 3 4 4
Mean Estimate 1.51 1.57 6.16 6.58
High Estimates 1.63 1.65 6.27 7.02
Low Estimate 1.41 1.41 6.07 6.17
Coefficient of Variance 6.08 8.72 1.41 5.95

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Collegium Pharmaceutical Inc - COLL

Date Name Shares Transaction Value
Jun 6, 2024 Shirley R. Kuhlmann EVP and General Counsel 139,409 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.22 per share 4,631,166.98
Jun 6, 2024 Shirley R. Kuhlmann EVP and General Counsel 140,109 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.55 per share 4,560,547.95
May 30, 2024 Colleen Tupper EVP & Chief Financial Officer 130,845 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.21 per share 4,476,207.45
May 29, 2024 Scott Dreyer EVP & Chief Commercial Officer 190,127 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.03 per share 4,568,751.81
May 29, 2024 Scott Dreyer EVP & Chief Commercial Officer 23,791 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 29, 2024 Scott Dreyer EVP & Chief Commercial Officer 105,902 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.98 per share 3,598,549.96
May 29, 2024 Scott Dreyer EVP & Chief Commercial Officer 162,709 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.03 per share 3,909,897.27
May 29, 2024 Scott Dreyer EVP & Chief Commercial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 29, 2024 Scott Dreyer EVP & Chief Commercial Officer 138,918 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.82 per share 4,698,206.76
May 17, 2024 Gwen A. Melincoff Director 52,468 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Neil F. McFarlane Director 49,365 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 John A. Fallon Director 54,843 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Michael Thomas Heffernan Director 45,508 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Garen G. Bohlin Director 73,760 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.73 per share 422,644.80
May 17, 2024 Rita Balice-Gordon Director 46,488 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 John Gordon Freund Director 52,468 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Gino Santini Director 75,656 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Garen G. Bohlin Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 17, 2024 Garen G. Bohlin Director 52,468 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Garen G. Bohlin Director 44,775 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.3 per share 1,446,232.50

Collegium Pharmaceutical Inc in the News